Biotech News

Founded and led by Gary Glick, Odyssey Therapeutics has raised $218 million in an initial fundraising round for its cancer and inflammatory disease drug research.

Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy ntaylor Tue, 12/07/2021 - 05:44

Surrozen's ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.

GlaxoSmithKline, Medicago hit 75% efficacy against delta COVID strain, but omicron muddies waters badams Mon, 12/06/2021 - 14:55

Apple Tree Partners breaks into UK with biotech Adendra Therapeutics launch, $53M series A raise elucas Mon, 12/06/2021 - 13:42

Like Pfizer's Xeljanz, the label for AbbVie's Rinvoq has been updated to warn about risks of death and major cardiovascular events like stroke.

The emergency clearance from the FDA allows for treatment of mild and moderate disease as well as prevention in those exposed and at high risk.

The biotech's drug, called zavegepant, is delivered intranasally and could offer a similar convenience advantage as its first, the fast-selling Nurtec ODT.

Could Viagra prevent and treat Alzheimer's? Cleveland Clinic team shows its potential arlene.weintraub Mon, 12/06/2021 - 09:57

Biohaven pain spray aces test as C-suite shake-up sees incoming CFO, chief in chairman role badams Mon, 12/06/2021 - 09:48

Investors punish Aeglea for missed rare disease secondaries, sending stock spiraling despite primary endpoint success ntaylor Mon, 12/06/2021 - 08:58

Adicet soars on early responses to gamma delta CAR-T therapy ntaylor Mon, 12/06/2021 - 08:19

How will your digital advertising strategy evolve in a future without cookies?

Genetic variant linked to Amish community could pave way for new heart disease therapies klahucik Sun, 12/05/2021 - 17:48

Usama Malik, chief financial officer of Immunomedics from 2017 to late 2020, is charged with tipping his partner and several relatives of positive study results for the biotech's breast cancer drug.

Three months after proposing a roughly $8 billion acquisition of Sobi, the investment firms Advent International and GIC have withdrawn their offer.

Gene therapy startup bursts forth from incubation at J&J and F-Prime, graduating with $80M and a Novartis veteran at the helm ntaylor Fri, 12/03/2021 - 07:24

Little European biotech Sotio nabs a super $316M funding round for its superagonist work badams Fri, 12/03/2021 - 05:22

BeyondSpring lurches down as FDA rejects plinabulin, raising questions about lung cancer prospects ntaylor Fri, 12/03/2021 - 03:48

The takeover of the Spanish firm Sanifit by Vifor Pharma in Switzerland marks a high point for the life sciences sector in Spain, which has seen a burst of acquisitions this year. Last month, Vifor Pharma acquired Sanifit in a deal worth up to €375M, hailed as one of the biggest-ever biotech acquisitions in Spain. The aim was to get hold of Sanifit’s lead drug: a first-in-class treatment to prevent the buildup of mineral deposits in the blood vessels of patients with advanced kidney disease. Sanifit’s landmark acquisition comes two years after the Mallorca-based company raised €72.2M in 2019, a record private round for Spanish biotech. The company’s success has proved pivotal for increasing investor awareness of Spanish life sciences companies. “When we started Sanifit in 2004, we faced a completely different situation: there was no biotech ecosystem in Spain and most investors were based abroad,” said Sanifit’s CEO, Joan Perelló. The increasing tally of Spanish venture capital (VC) firms over the years helped to change the tide. The post Sanifit Seals Booming Acquisition Year for Spanish Life Sciences appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Fore fires CEO Malik after SEC insider trading charges during his time as Immunomedics CFO klahucik Thu, 12/02/2021 - 12:52

UCB's experimental pill is one of the most advanced projects that's aimed at blocking accumulation of an abnormal protein in patients' brains.

Equipped with $40 million in funding, a new institute from GSK and Oxford will initially focus on developing treatments for Alzheimer's, Parkinson's, ALS and other neurological conditions.

AviadoBio, which was built around research from the lab of Christopher Shaw at King's College London, is backed by venture firms NEA and Monograph Capital.

Alpha challenger: Novartis pays UCB $150M to join Roche, AstraZeneca in Parkinson's race ntaylor Thu, 12/02/2021 - 07:48